Congratulations on a trade with Ritter Pharma (NASDAQ : RTTR).
Today Ritter (Company) announced that the U.S. Food and Drug Administration (FDA) has agreed to schedule an end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017. The Company plans to discuss the results of its recently completed phase 2b/3 trial and phase 3 plans in preparation of a New Drug Application (NDA) submission of RP-G28 for the treatment of lactose intolerance. The completed phase 2b/3 trial demonstrated several positive topline results and full analysis of the data is underway. The trial was the largest well-controlled clinical study ever conducted in lactose intolerance.
New trading idea is for PennyStockHaven’s followers: ParkerVision, Inc. (NASDAQ: PRKR)
ParkerVision, Inc. (NASDAQ: PRKR) designs, develops, and markets proprietary radio frequency (RF) technologies and products for use in wireless communication products and applications in the United States and offers technologies for processing RF waveforms in wireless applications. ParkerVision also provides engineering consulting and design services to its customers to assist them in developing prototypes and/or products incorporating its technologies. It focuses on incorporating its technologies into various markets that incorporate RF transmitters, receivers, and/or transceivers, including mobile handsets, tablets, femtocells, digital television, machine-to-machine products, RF identification, cable modems, satellite communication, infrastructure, and others.